Jose Fernando Prado Moura

Dr. Jose Fernando Prado Moura


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Saúde em Debate
Verified
Journal Article
Open access
PDF file
MSMaria Rejane Ferreira da Silva
Maria Rejane Ferreira da Silva
JBJoão Paulo Reis Braga
João Paulo Reis Braga
JMJose Fernando Prado Moura
Jose Fernando Prado Moura
JLJurema Telles de Oliveira Lima
Jurema Telles de Oliveira Lima
RESUMO O objetivo do estudo foi analisar a continuidade da assistência a mulheres com câncer de colo uterino. Estudo de caso qualitativo, em redes de saúde. Realizaram-se entrevistas com roteiro semiestruturado e técnica de análise narrativa de conteúdo. As mulheres perceberam barreiras no diagnóstico, no tratamento e na acessibilidade entre níveis de atenção. Observaram comunicação informal entre especialistas; limitações na comunicação entre níveis de atenção; inexistência de contrarreferência; e que o vínculo paciente-serviço era maior na esfera da oncologia. A falta de contrarreferência dificultou a acumulação de conhecimento e a coordenação do cuidado pela Atenção Básica.

5 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
FMFabio Postiglione Mansani
Fabio Postiglione Mansani
RFRuffo Frritas-Junior
Ruffo Frritas-Junior
WMWellerson de Aguiar Miranda
Wellerson de Aguiar Miranda
ABAntonio Carlos Buzaid
Antonio Carlos Buzaid
AFAntonio Luiz Frasson
Antonio Luiz Frasson
ASAna Luiza Lima Sousa
Ana Luiza Lima Sousa
Purpose: The MammaPrint™ (MP) 70-gene signature, identifies hormone receptor-positive (HR+), HER2-negative breast cancer patients with low genomic risk who are candidates for de-escalation of the systemic therapies employed. Knowing that MP was validated in an exclusively European cohort and understanding the heterogeneity of breast tumors in different populations, we proposed a study to analyze MP performance in the Brazilian population. Methods: Retrospective, prognostic evaluation, real-world cohort study of HR+, HER2- breast cancer patients who underwent MP in Brazil from January 2016 to December 2020 (AGEMA-BRA). Results: Of the 953 patients with high clinical risk, 407 (42.7%) had high genomic risk, and 546 (57.3%) had low genomic risk to MP. In the analysis of epidemiological, clinical, and anato-mopathological data correlating high and low risk to MP, and among the subgroups with low-risk, ultra-low risk, high-risk 1 and high-risk 2, only the histological grade showed statistical significance. Distant metastasis-free survival (DMFS) was 97.8% and overall survival (OS) was 99.8% with a mean follow-up of 40.8 months, with no difference between high and low genomic risk. Conclusions: Applying the MP signature in the AGEMA-BRA cohort enabled greater chemotherapy de-escalation with better DMFS than observed in the MINDACT pivotal study. Equivalent DMFS and OS results between high and low genomic risk carriers demonstrate the appropriate selection of patients by MP to receive or not receive adjuvant chemotherapy. These data make it possible to validate the performance of the signature in the Brazilian population and confirm the importance of testing it in different populations.